ICER Expands Drug Value Comparison Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The non-profit Institute for Clinical and Economic Review plans comparative value and price assessments for up to 20 new drugs over the next two years, supported by grant funding.
You may also be interested in...
Valuing Drugs In The US: How We're Doing And What's Ahead
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.
Medicare Wastage Rebate Exceptions For Small Volume Products, Cell/Gene Therapy Urged
Packaging for such products reflects ‘unique circumstances’ that should exempt them from the rebates on discarded drugs otherwise required by the policy, stakeholders tell CMS at a ‘town hall’ forum.
Pharma Gets 340B Appeals Court Victory But More Decisions Are Pending; Will Congress Step In?
Third Circuit is first of three federal appeals courts to issue a decision in multiple lawsuits over drug companies’ 340B contract pharmacy restrictions, which have led to conflicting lower court rulings on whether such restrictions are unlawful.